Work with LifeSpan to design a custom immunohistochemistry to address your specific biological question. Outsource the entire localization process without having to
worry about finding and characterizing target specific antibodies, sourcing and validating difficult-to-find tissues, and having the ability to interpret the resulting
immunostaining in relation to complex human pathologies.
TCR Screening Services
Test your therapeutic antibodies in immunohistochemistry against a broad panel of normal frozen human tissue types in order to determine potential unintended binding.
Our non-GLP TCR services are designed on the FDA recommendation outlined in their "Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use".
Mouse Monoclonal [clone DCS-60.2] (IgG2a) to Human CDKN1A / WAF1 / p21
Human CDKN1A / WAF1 / p21
Human (tested or 100% immunogen sequence identity)
IgG2a Monoclonal [DCS-60.2]
Specificity and Use
CDKN1A / WAF1 / p21 antibody was raised against bALB/C mice were injected with a full length human recombinant p21 protein.
Recognizes a 21 kD protein identified as p21WAF1/Cip1/Sdi1/Pic1 tumor suppressor protein. This antibody is highly specific to p21 and does not show any cross reactivity to other mitotic inhibitors. This antibody does not cross react with mouse and rat.
CDKN1A / WAF1 / p21 is a potent cyclin-dependent kinase inhibitor. The encoded protein binds to and inhibits the activity of cyclin-CDK2 or -CDK4 complexes, and thus functions as a regulator of cell cycle progression at G1. The expression of this gene is tightly controlled by the tumor suppressor protein p53, through which this protein mediates the p53-dependent cell cycle G1 phase arrest in response to a variety of stress stimuli.